Hormonal
GLP1R agonism reduces coronary artery disease (CAD) risk primarily through body weight lowering (BMI) rather than through the reduction of type 2 diabetes (T2D) liability.
If you are using a GLP-1 agonist (like semaglutide or tirzepatide) for heart health, the primary benefit comes from the weight loss it induces, not just from lowering blood sugar. Even if your blood sugar is already well-controlled, the drug's effect on reducing body weight is what significantly lowers your risk of coronary artery disease. This supports using these medications for cardiovascular prevention in obese individuals, regardless of diabetic status.
Multivariable Mendelian randomization analyses that were corrected for overdispersion heterogeneity suggest that bodyweight lowering rather than T2D liability lowering effects of GLP1R agonism are more likely contributing to reduced CAD risk.
Why this rating
Uses robust Mendelian Randomization with large sample sizes and novel statistical corrections for heterogeneity, though it is an observational genetic proxy rather than a randomized clinical trial of the drug itself.
Source
Robust use of phenotypic heterogeneity at drug target genes for mechanistic insights: Application of <i>cis</i>‐multivariable Mendelian randomization to <i>GLP1R</i> gene region
Ashish Patel et al. · Genetic Epidemiology · 2024
DOI 10.1002/gepi.22551
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →